Aligned Genetics Inc (238120) - Total Liabilities
Based on the latest financial reports, Aligned Genetics Inc (238120) has total liabilities worth ₩9.61 Billion KRW (≈ $6.51 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Aligned Genetics Inc (238120) long-term investment share to see how much of total assets are deployed in long-term investments.
Aligned Genetics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Aligned Genetics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aligned Genetics Inc balance sheet assets.
Aligned Genetics Inc Competitors by Total Liabilities
The table below lists competitors of Aligned Genetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Primary Health Properties
LSE:PHP
|
UK | GBX3.54 Billion |
|
Centric Holdings S.A
AT:CENTR
|
Greece | €11.16 Million |
|
Karolinska Development AB ser. B
ST:KDEV
|
Sweden | Skr6.55 Million |
|
Jeongsan Aikang Co.Ltd
KQ:022220
|
Korea | ₩63.02 Billion |
|
Sung Bo Chem
KO:003080
|
Korea | ₩78.41 Billion |
|
Cobalt Blue Holdings Ltd
AU:COB
|
Australia | AU$3.69 Million |
|
Rocketboots Ltd
AU:ROC
|
Australia | AU$2.01 Million |
|
Guler Yatirim Holding AS
IS:GLRYH
|
Turkey | TL10.53 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Aligned Genetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 238120 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aligned Genetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aligned Genetics Inc (2015–2024)
The table below shows the annual total liabilities of Aligned Genetics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩8.78 Billion ≈ $5.95 Million |
-8.73% |
| 2023-12-31 | ₩9.62 Billion ≈ $6.52 Million |
+19.48% |
| 2022-12-31 | ₩8.05 Billion ≈ $5.46 Million |
+7.68% |
| 2021-12-31 | ₩7.48 Billion ≈ $5.07 Million |
+86.12% |
| 2020-12-31 | ₩4.02 Billion ≈ $2.72 Million |
+9.99% |
| 2019-12-31 | ₩3.65 Billion ≈ $2.48 Million |
+72.88% |
| 2018-12-31 | ₩2.11 Billion ≈ $1.43 Million |
+26.75% |
| 2017-12-31 | ₩1.67 Billion ≈ $1.13 Million |
-0.67% |
| 2016-12-31 | ₩1.68 Billion ≈ $1.14 Million |
+110.80% |
| 2015-12-31 | ₩796.04 Million ≈ $539.46K |
-- |
About Aligned Genetics Inc
Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genet… Read more